LeHavreV1, Pmc, Corpus, bibRecord, 000084

Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis

Identifieur interne : 000084 ( Pmc/Corpus ); précédent : 000083; suivant : 000085

Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis

Auteurs : E. Dannaoui ; M. Abdul ; M. Arpin ; A. Michel-Nguyen ; M. A. Piens ; A. Favel ; O. Lortholary ; F. Dromer

Source :

Antimicrobial Agents and Chemotherapy [ 0066-4804 ] ; 2006.

RBID : PMC:1489793

Abstract

The in vitro susceptibilities of Cryptococcus neoformans isolates from consecutive human immunodeficiency virus-positive and -negative patients to the antifungal agents fluconazole, amphotericin B, and flucytosine were determined by different techniques, including the CLSI method, Etest, and broth microdilution in yeast nitrogen base (YNB) medium, during a multicenter prospective study in France. The relationship between the in vitro data and the clinical outcome 2 weeks after the initiation of antifungal therapy was assessed. In addition, the correlation between the strain serotype and the in vitro activities of the antifungals was determined, and the susceptibility results obtained with the different techniques were also compared. Thirty-seven patients received a combination of amphotericin B with flucytosine as first-line therapy, 22 were treated with amphotericin B alone, and 15 received fluconazole alone. Whatever the antifungal tested, there was no trend toward higher MICs for strains isolated from patients who failed to respond to a given therapy compared to those from patients who did not with either the CLSI method, Etest, or broth microdilution in YNB medium. The MICs obtained by the CLSI or Etest method were significantly lower for serotype D strains than for serotype A strains for both fluconazole and amphotericin B, while flucytosine MICs were not different according to serotype. These findings suggest that the in vitro antifungal susceptibility of C. neoformans, as determined with the techniques used, is not able to predict the early clinical outcome in patients with cryptococcosis.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1489793

DOI: 10.1128/AAC.01520-05
PubMed: 16801427
PubMed Central: 1489793

Links to Exploration step

PMC:1489793

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis</title>
<author><name sortKey="Dannaoui, E" sort="Dannaoui, E" uniqKey="Dannaoui E" first="E." last="Dannaoui">E. Dannaoui</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Abdul, M" sort="Abdul, M" uniqKey="Abdul M" first="M." last="Abdul">M. Abdul</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Arpin, M" sort="Arpin, M" uniqKey="Arpin M" first="M." last="Arpin">M. Arpin</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Michel Nguyen, A" sort="Michel Nguyen, A" uniqKey="Michel Nguyen A" first="A." last="Michel-Nguyen">A. Michel-Nguyen</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Piens, M A" sort="Piens, M A" uniqKey="Piens M" first="M. A." last="Piens">M. A. Piens</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Favel, A" sort="Favel, A" uniqKey="Favel A" first="A." last="Favel">A. Favel</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lortholary, O" sort="Lortholary, O" uniqKey="Lortholary O" first="O." last="Lortholary">O. Lortholary</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dromer, F" sort="Dromer, F" uniqKey="Dromer F" first="F." last="Dromer">F. Dromer</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">16801427</idno>
<idno type="pmc">1489793</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1489793</idno>
<idno type="RBID">PMC:1489793</idno>
<idno type="doi">10.1128/AAC.01520-05</idno>
<date when="2006">2006</date>
<idno type="wicri:Area/Pmc/Corpus">000084</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis</title>
<author><name sortKey="Dannaoui, E" sort="Dannaoui, E" uniqKey="Dannaoui E" first="E." last="Dannaoui">E. Dannaoui</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Abdul, M" sort="Abdul, M" uniqKey="Abdul M" first="M." last="Abdul">M. Abdul</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Arpin, M" sort="Arpin, M" uniqKey="Arpin M" first="M." last="Arpin">M. Arpin</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Michel Nguyen, A" sort="Michel Nguyen, A" uniqKey="Michel Nguyen A" first="A." last="Michel-Nguyen">A. Michel-Nguyen</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Piens, M A" sort="Piens, M A" uniqKey="Piens M" first="M. A." last="Piens">M. A. Piens</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Favel, A" sort="Favel, A" uniqKey="Favel A" first="A." last="Favel">A. Favel</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lortholary, O" sort="Lortholary, O" uniqKey="Lortholary O" first="O." last="Lortholary">O. Lortholary</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Dromer, F" sort="Dromer, F" uniqKey="Dromer F" first="F." last="Dromer">F. Dromer</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Antimicrobial Agents and Chemotherapy</title>
<idno type="ISSN">0066-4804</idno>
<idno type="eISSN">1098-6596</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The in vitro susceptibilities of <italic>Cryptococcus neoformans</italic>
 isolates from consecutive human immunodeficiency virus-positive and -negative patients to the antifungal agents fluconazole, amphotericin B, and flucytosine were determined by different techniques, including the CLSI method, Etest, and broth microdilution in yeast nitrogen base (YNB) medium, during a multicenter prospective study in France. The relationship between the in vitro data and the clinical outcome 2 weeks after the initiation of antifungal therapy was assessed. In addition, the correlation between the strain serotype and the in vitro activities of the antifungals was determined, and the susceptibility results obtained with the different techniques were also compared. Thirty-seven patients received a combination of amphotericin B with flucytosine as first-line therapy, 22 were treated with amphotericin B alone, and 15 received fluconazole alone. Whatever the antifungal tested, there was no trend toward higher MICs for strains isolated from patients who failed to respond to a given therapy compared to those from patients who did not with either the CLSI method, Etest, or broth microdilution in YNB medium. The MICs obtained by the CLSI or Etest method were significantly lower for serotype D strains than for serotype A strains for both fluconazole and amphotericin B, while flucytosine MICs were not different according to serotype. These findings suggest that the in vitro antifungal susceptibility of <italic>C. neoformans</italic>
, as determined with the techniques used, is not able to predict the early clinical outcome in patients with cryptococcosis.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id>
<journal-id journal-id-type="publisher-id">aac</journal-id>
<journal-title>Antimicrobial Agents and Chemotherapy</journal-title>
<issn pub-type="ppub">0066-4804</issn>
<issn pub-type="epub">1098-6596</issn>
<publisher><publisher-name>American Society for Microbiology</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">16801427</article-id>
<article-id pub-id-type="pmc">1489793</article-id>
<article-id pub-id-type="publisher-id">1520-05</article-id>
<article-id pub-id-type="doi">10.1128/AAC.01520-05</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Susceptibility</subject>
</subj-group>
</article-categories>
<title-group><article-title>Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Dannaoui</surname>
<given-names>E.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff1">2</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Abdul</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Arpin</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Michel-Nguyen</surname>
<given-names>A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">5</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Piens</surname>
<given-names>M. A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Favel</surname>
<given-names>A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">6</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Lortholary</surname>
<given-names>O.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff1">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Dromer</surname>
<given-names>F.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author"><collab>the French Cryptococcosis Study Group<xref ref-type="fn" rid="fn1">†</xref>
</collab>
</contrib>
</contrib-group>
<aff id="aff1">Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, CNRS FRE2849, Institut Pasteur, 75724 Paris Cedex 15, France,<label>1</label>
 Université Paris Descartes, Faculté de Médecine, AP-HP, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, 75015 Paris, France,<label>2</label>
 Université Paris Descartes, Faculté de Médecine, AP-HP, Hôpital Necker-Enfants-Malades, Service des Maladies Infectieuses et Tropicales, 75743 Paris Cedex 15, France,<label>3</label>
 Laboratoire de Parasitologie, Mycologie Médicale et Pathologie Exotique, Université Claude Bernard Lyon I, 69373 Lyon Cedex 08, France,<label>4</label>
 Laboratoire de Microbiologie, CHU Timone, and Hôpital St. Joseph, 13000 Marseille, France,<label>5</label>
 Laboratoire de Botanique, Cryptogamie et Biologie Cellulaire, Faculté de Pharmacie, 13385 Marseille Cedex 5, France<label>6</label>
</aff>
<author-notes><fn id="cor1"><label>*</label>
<p>Corresponding author. Mailing address: Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, CNRS FRE2849, Institut Pasteur, 25, rue du Dr. Roux, 75724 Paris Cedex 15, France. Phone: 33 1 40 61 32 50. Fax: 33 1 45 68 84 20. E-mail: <email>dannaoui@pasteur.fr</email>
.</p>
</fn>
<fn id="fn1"><label>†</label>
<p>The members of the French Cryptococcosis Study Group are listed in Acknowledgments.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub"><month>7</month>
<year>2006</year>
</pub-date>
<volume>50</volume>
<issue>7</issue>
<fpage>2464</fpage>
<lpage>2470</lpage>
<history><date date-type="received"><day>28</day>
<month>11</month>
<year>2005</year>
</date>
<date date-type="rev-recd"><day>14</day>
<month>2</month>
<year>2006</year>
</date>
<date date-type="accepted"><day>21</day>
<month>4</month>
<year>2006</year>
</date>
</history>
<copyright-statement>Copyright © 2006, American Society for Microbiology</copyright-statement>
<copyright-year>2006</copyright-year>
<self-uri xlink:title="pdf" xlink:href="zac00706002464.pdf"></self-uri>
<abstract><p>The in vitro susceptibilities of <italic>Cryptococcus neoformans</italic>
 isolates from consecutive human immunodeficiency virus-positive and -negative patients to the antifungal agents fluconazole, amphotericin B, and flucytosine were determined by different techniques, including the CLSI method, Etest, and broth microdilution in yeast nitrogen base (YNB) medium, during a multicenter prospective study in France. The relationship between the in vitro data and the clinical outcome 2 weeks after the initiation of antifungal therapy was assessed. In addition, the correlation between the strain serotype and the in vitro activities of the antifungals was determined, and the susceptibility results obtained with the different techniques were also compared. Thirty-seven patients received a combination of amphotericin B with flucytosine as first-line therapy, 22 were treated with amphotericin B alone, and 15 received fluconazole alone. Whatever the antifungal tested, there was no trend toward higher MICs for strains isolated from patients who failed to respond to a given therapy compared to those from patients who did not with either the CLSI method, Etest, or broth microdilution in YNB medium. The MICs obtained by the CLSI or Etest method were significantly lower for serotype D strains than for serotype A strains for both fluconazole and amphotericin B, while flucytosine MICs were not different according to serotype. These findings suggest that the in vitro antifungal susceptibility of <italic>C. neoformans</italic>
, as determined with the techniques used, is not able to predict the early clinical outcome in patients with cryptococcosis.</p>
</abstract>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Pmc/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000084 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000084 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/France
   |area=    LeHavreV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:1489793
   |texte=   Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:16801427" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LeHavreV1

This area was generated with Dilib version V0.6.25.
Data generation: Sat Dec 3 14:37:02 2016. Site generation: Tue Mar 5 08:25:07 2024

	Serveur d'exploration sur la visibilité du Havre
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la visibilité du Havre

Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis

Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki